AlzeCure Pharma
4.11.2021 10:21:53 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 04, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company's latest developments. The presentation will be followed by a Q&A with external experts on-site and Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815899/redeye-life-science-day-2021 . The recorded presentation and the slide set will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Life Science Day 2021 on November 11
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/671149/AlzeCure-Presents-at-Redeye-Life-Science-Day-2021-on-November-11
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Promotes Kevin Gee to Vice President of Pro Product Development - FLEX28.9.2026 14:25:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / September 28, 2026 / Chervon promotes Kevin Gee to Vice President of Pro Product Development - FLEX, effective Monday, September 28, 2026, reporting to CEO Joe Galli. Kevin Gee joined Chervon after a 15-year international career in the Milwaukee Pro Power Tool business. He started his career at TTI in 2011 as a Field Sales Store Representative in Toronto, Ontario. He moved through several Milwaukee marketing positions in Canada and was then promoted to a marketing position with Milwaukee based in Hong Kong in 2013. He then rose to the position of Group Marketing Manager in Milwaukee Asia in 2016. In 2017, Kevin was moved to Milwaukee U.S.A. and advanced through a series of Milwaukee product management positions from 2017 to 2023. His final position was Director of Product Management for Milwaukee Pro Tools from 2021 to 2023. Most recently, Kevin held the position of Chief Revenue and Marketing Officer for Guardian Safety Equipment before joining Cherv
Chervon Names Trevor Bithrey Vice President Pro End User Marketing and Research - Canada28.9.2026 14:25:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / September 28, 2026 / Trevor Bithrey joins Chervon as Vice President, Pro End User Marketing and Research - Canada, effective Monday, September 28, reporting to CEO Joe Galli. Bithrey joins Chervon with over 25 years of professional power tools experience. He has excelled in his increasingly responsible positions in building both the DeWalt Canada business and the Milwaukee Canada business. He brings an impressive and diverse skillset in account management, end user marketing, aftersales service and end user research. He also has experience building and leading exceptional teams in Canada. Bithrey will also be part of the newly formed Chervon Global End User Research and Jobsite Marketing team, reporting directly to CEO Joe Galli. Bithrey's career started at DeWalt Canada where he held a series of sales and product management positions from 2000 to 2007. He then moved to Milwaukee Canada from 2007 until 2023 where he advanced through key leadership rol
Fermi Selects NAES to Operate and Maintain Its Natural Gas Turbine Fleet28.9.2026 13:00:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / September 28, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today an operations and maintenance (O&M) agreement with NAES Corporation ("NAES"), the largest independent operator of power plants in the United States. Under the agreement, NAES will run and maintain Fermi's natural gas turbine fleet at its Project Matador private-power campus in Carson County, Texas. "This agreement puts a proven and experienced operator in place that has been running power plants for more than 45 years," said Lee McIntire, Fermi Chief Executive Officer. "Our first customer is signed, our turbines are secured, and our EPC partners are on board. Now, with NAES, we're adding an operating partner with operations and maintenance depth, skilled crews, and proven management systems before the first natural-gas generation units come online. That protects uptime for the customers who are counting on us for quality and rel
Camino Receives Environmental Approval for Significant Exploration Expansion at the Costa de Cobre Copper Project in Peru28.9.2026 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / September 28, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that its Peruvian subsidiary, a 65/35 joint venture between Camino and Nittetsu Mining Co., Ltd. ("Nittetsu"), has received approval from Peru's Ministry of Energy and Mines ("MINEM") for the Second Modification of the Semi-Detailed Environmental Impact Assessment ("Second MEIA-sd") for its Costa de Cobre Project (formerly known and referred to in the permit as Los Chapitos), along the coastline in southern Peru. The approval represents a major milestone for Costa de Cobre, increasing the effective exploration area by approximately 94%, from 6,012.50 hectares to 11,671.90 hectares, and expanding the environmental framework to support a total of 280 drill platforms and up to 611,840 metres of drilling capacity, covering major portions of the three copper fault trends crossing Camino's claims: Diva trend; La Estancia trend; and the
Case IQ Launches Quantum Approvals & Disclosures So Compliance Teams Find Risk Earlier28.9.2026 10:00:00 CEST | Press release
LONDON, GB / ACCESS Newswire / September 28, 2026 / Case IQ, a leading provider of compliance and risk management solutions, today announced the launch of Quantum Approvals & Disclosures, a native AI-powered solution designed to help organisations identify risk earlier, reduce manual effort, and make more consistent, defensible compliance decisions. In addition to the embedded governed AI capabilities that support employees and compliance reviewers, the solution launches with two ready-to-use AI agents, Submission Support and Risk Spotlight. Employees receive intelligent guidance that helps them submit more complete and accurate information, while compliance teams gain the context needed to prioritise higher-risk activity and proactively engage before potential issues escalate. The solution supports complex approval and disclosure programmes spanning conflicts of interest, gifts and hospitality, donations and sponsorships, and other risk areas. By bringing submissions, reviews, decisio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom